

Special Issue

Vaccines in Farm Animals

Message from the Guest Editors

In this special issue we focus on the development, characterization, field trials and efficiency tests of vaccines aimed at stopping or preventing diseases affecting animals and humans, with an especial interest in those related to livestock. To this end, we invite you to submit an original research or review to this Special Issue covering (but not limited to) the following topics: a) Vaccines against protozoan parasites (e.g. *Toxoplasma*, *Neospora*, *Eimeria*, *Theileria*, *Tritrichomonas*...) b) Vaccines against diseases affecting ruminants, with especial interest in those vertically transmitted or causing abortion (protozoans, viruses, bacteria...) c) Vaccines against diseases transmitted to humans through animal products (meat, milk, eggs...) d) Recombinant or inactivated vaccine trials in livestock (cattle, sheep, goat, poultry, pigs...) e) Vaccines based on genetically modified organisms affecting animals and humans (knockout, exogenous expression of heterologous proteins/antigens) We are looking forward to your interesting manuscript and do not hesitate to contact us should you require further information.

Guest Editors

Dr. David Arranz-Solís
Dr. Yanina Paola Hecker
Dr. Valentin Pérez

Deadline for manuscript submissions

closed (31 July 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/88544

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).